Codagenix Welcomes Bruce Taillon as Executive Vice President of Animal Health
Retrieved on:
Wednesday, January 12, 2022
Business development, Foot-and-mouth disease virus, Research, Technology, Degenerative disease, University, Vaccine, Roche Diagnostics, Dog, United States Department of Agriculture, Solution, Farmer, Animal Health, Leadership, National Institute, Health, Disease management, Animal, View, National Academy of Sciences, Miniature pig, Multimedia, Eunice Kennedy Shriver National Institute of Child Health and Human Development, Carnegie Mellon University, Washington University in St. Louis, Livestock, Horse, Business, National academy, Drug discovery, National Society of Certified Healthcare Business Consultants, List of life sciences, Management, Biology, Taillon
FARMINGDALE, N.Y., Jan. 12, 2022 /PRNewswire/ -- Codagenix, Inc., a clinical-stage synthetic biology company pioneering a novel platform for vaccines and oncolytic virus therapies, today announced the appointment of Bruce E. Taillon, Ph.D., as Executive Vice President of Animal Health.
Key Points:
- FARMINGDALE, N.Y., Jan. 12, 2022 /PRNewswire/ -- Codagenix, Inc., a clinical-stage synthetic biology company pioneering a novel platform for vaccines and oncolytic virus therapies, today announced the appointment of Bruce E. Taillon, Ph.D., as Executive Vice President of Animal Health.
- "His vast knowledge and passion for animal health is evident in his diverse track recordfrom technical operations to vaccine development and pharmaceutical innovation."
- Prior to joining Codagenix, Taillon served as Senior Director of External Innovation & Business Development of Elanco Animal Health, where he led a global team in the identification and evaluation of new and innovative animal health solutions.
- "I'm thrilled to join the progressive team at Codagenix as they pioneer new frontiers in vaccine development for animals," said Taillon, Executive Vice President of Animal Health at Codagenix.